Thessa Kroes

Thessa Kroes

Auto-generated profile, based on publicly available information

Thessa Kroes

Adelaide Medical School and Robinson Research Institute University of Adelaide Adelaide South Australia Australia

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JLJoep de Ligt
Joep de Ligt
MWMarjolein H. Willemsen
Marjolein H. Willemsen
BBBregje W.M. van Bon
Bregje W.M. van Bon
TKTjitske Kleefstra
Tjitske Kleefstra
HYHelger G. Yntema
Helger G. Yntema
LVLisenka E.L.M. Vissers
Lisenka E.L.M. Vissers
The causes of intellectual disability remain largely unknown because of extensive clinical and genetic heterogeneity. We evaluated patients with intellectual disability to exclude known causes of the disorder. We then sequenced the coding regions of more than 21,000 genes obtained from 100 patients with an IQ below 50 and their unaffected parents. A data-analysis procedure was developed to identify and classify de novo, autosomal recessive, and X-linked mutations. In addition, we used high-throughput resequencing to confirm new candidate genes in 765 persons with intellectual disability (a confirmation series). All mutations were evaluated by molecular geneticists and clinicians in the context of the patients' clinical presentation. We identified 79 de novo mutations in 53 of 100 patients. A total of 10 de novo mutations and 3 X-linked (maternally inherited) mutations that had been previously predicted to compromise the function of known intellectual-disability genes were found in 13 patients. Potentially causative de novo mutations in novel candidate genes were detected in 22 patients. Additional de novo mutations in 3 of these candidate genes were identified in patients with similar phenotypes in the confirmation series, providing support for mutations in these genes as the cause of intellectual disability. We detected no causative autosomal recessive inherited mutations in the discovery series. Thus, the total diagnostic yield was 16%, mostly involving de novo mutations. De novo mutations represent an important cause of intellectual disability; exome sequencing was used as an effective diagnostic strategy for their detection. (Funded by the European Union and others.)

24 February 2012 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
MWMarjolein H Willemsen
Marjolein H Willemsen
LVLisenka E L Vissers
Lisenka E L Vissers
MWMichèl A A P Willemsen
Michèl A A P Willemsen
BBBregje W M van Bon
Bregje W M van Bon
TKThessa Kroes
Thessa Kroes
TKTjitske Kleefstra
Tjitske Kleefstra
Background: DYNC1H1 encodes the heavy chain protein of the cytoplasmic dynein 1 motor protein complex that plays a key role in retrograde axonal transport in neurons. Furthermore, it interacts with the LIS1 gene of which haploinsufficiency causes a severe neuronal migration disorder in humans, known as classical lissencephaly or Miller-Dieker syndrome. Aim: To describe the clinical spectrum and molecular characteristics of DYNC1H1 mutations. Methods: A family based exome sequencing approach was used to identify de novo mutations in patients with severe intellectual disability. Results: In this report the identification of two de novo missense mutations in DYNC1H1 (p.Glu1518Lys and p.His3822Pro) in two patients with severe intellectual disability and variable neuronal migration defects is described. Conclusion: Since an autosomal dominant mutation in DYNC1H1 was previously identified in a family with the axonal (type 2) form of Charcot- Marie-Tooth (CMT2) disease and mutations in Dync1h1 in mice also cause impaired neuronal migration in addition to neuropathy, these data together suggest that mutations in DYNC1H1 can lead to a broad phenotypic spectrum and confirm the importance of DYNC1H1 in both central and peripheral neuronal functions.

29 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
RFRahel T. Florian
Rahel T. Florian
FKFlorian Kraft
Florian Kraft
ELElsa Leitão
Elsa Leitão
SKSabine Kaya
Sabine Kaya
SKStephan Klebe
Stephan Klebe
CDChristel Depienne
Christel Depienne
Familial Adult Myoclonic Epilepsy (FAME) is a genetically heterogeneous disorder characterized by cortical tremor and seizures. Intronic TTTTA/TTTCA repeat expansions in SAMD12 (FAME1) are the main cause of FAME in Asia. Using genome sequencing and repeat-primed PCR, we identify another site of this repeat expansion, in MARCH6 (FAME3) in four European families. Analysis of single DNA molecules with nanopore sequencing and molecular combing show that expansions range from 3.3 to 14 kb on average. However, we observe considerable variability in expansion length and structure, supporting the existence of multiple expansion configurations in blood cells and fibroblasts of the same individual. Moreover, the largest expansions are associated with micro-rearrangements occurring near the expansion in 20% of cells. This study provides further evidence that FAME is caused by intronic TTTTA/TTTCA expansions in distinct genes and reveals that expansions exhibit an unexpectedly high somatic instability that can ultimately result in genomic rearrangements.

29 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
MCMark Corbett
Mark Corbett
TKThessa Kroes
Thessa Kroes
LVLiana Veneziano
Liana Veneziano
MBMark F. Bennett
Mark F. Bennett
RFRahel Florian
Rahel Florian
JGJozef Gecz
Jozef Gecz
Familial Adult Myoclonic Epilepsy (FAME) is characterised by cortical myoclonic tremor usually from the second decade of life and overt myoclonic or generalised tonic-clonic seizures. Four independent loci have been implicated in FAME on chromosomes (chr) 2, 3, 5 and 8. Using whole genome sequencing and repeat primed PCR, we provide evidence that chr2-linked FAME (FAME2) is caused by an expansion of an ATTTC pentamer within the first intron of STARD7. The ATTTC expansions segregate in 158/158 individuals typically affected by FAME from 22 pedigrees including 16 previously reported families recruited worldwide. RNA sequencing from patient derived fibroblasts shows no accumulation of the AUUUU or AUUUC repeat sequences and STARD7 gene expression is not affected. These data, in combination with other genes bearing similar mutations that have been implicated in FAME, suggest ATTTC expansions may cause this disorder, irrespective of the genomic locus involved.

16 March 2020 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
MBMark F. Bennett
Mark F. Bennett
KOKaren L. Oliver
Karen L. Oliver
BRBrigid M. Regan
Brigid M. Regan
SBSusannah T. Bellows
Susannah T. Bellows
ASAmy L. Schneider
Amy L. Schneider
MBMelanie Bahlo
Melanie Bahlo

13 April 2021 in Human Mutation
Verified
Journal Article
Open access
PDF file
MFMichael Field
Michael Field
RKRaman Kumar
Raman Kumar
AHAnna Hackett
Anna Hackett
SKSayaka Kayumi
Sayaka Kayumi
CSCheryl Shoubridge
Cheryl Shoubridge
MCMark Corbett
Mark Corbett
The pioneering discovery research of X‐linked intellectual disability (XLID) genes has benefitted thousands of individuals worldwide however, approximately 30% of XLID families still remain unresolved. We postulated that non‐coding variants that affect gene regulation or splicing may account for the lack of a genetic diagnosis in some cases. Detecting pathogenic, gene‐regulatory variants with the same sensitivity and specificity as structural and coding variants is a major challenge for Mendelian disorders. Here, we describe three pedigrees with suggestive XLID where distinctive phenotypes associated with known genes guided the identification of three different non‐coding variants. We used comprehensive structural, single nucleotide and repeat expansion analyses of genome sequencing. RNA‐Seq from patient‐derived cell lines, RT‐PCRs, western blots and reporter gene assays were used to confirm the functional effect of three fundamentally different classes of pathogenic non‐coding variants: a retrotransposon insertion, a novel intronic splice donor and a canonical splice variant of an untranslated exon. In one family, we excluded a rare coding variant in ARX, a known XLID gene, in favour of a regulatory non‐coding variant in OFD1 that correlated with the clinical phenotype. Our results underscore the value of genomic research on unresolved XLID families to aid novel, pathogenic non‐coding variant discovery.